Nasdaq stocks posting largest percentage decreases
AP - Wed May 07, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Fluidigm to Present at the Bank of America Merrill Lynch 2014 Healthcare Conference
Business Wire - Tue May 06, 8:03AM CDT
Fluidigm Corporation (NASDAQ:FLDM) today announced that Chief Financial Officer Vikram Jog and Vice President of Corporate Development Un Kwon-Casado will present at the Bank of America Merrill Lynch 2014 Healthcare Conference in Las Vegas, on Tuesday, May 13, 2014, at 2:20 p.m. (Pacific time).
Fluidigm Reports Q1 2014 Results
Business Wire - Mon May 05, 3:43PM CDT
Fluidigm Corporation (NASDAQ:FLDM) today announced its financial results for the first quarter ended March 31, 2014.
Commit To Purchase Fluidigm At $30, Earn 15.2% Annualized Using Options
at The Street - Fri May 02, 10:40AM CDT
Investors considering a purchase of Fluidigm Corp shares, but tentative about paying the going market price of $37.74/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract...
US Prenatal Testing Market 2014-2018: PerkinElmer Inc., Quest Diagnostics Inc., Sequenom Inc., and Verinata Health Dominate the Industry
M2 - Wed Apr 30, 5:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7lqfr2/prenatal_testing) has announced the addition of the "US Prenatal Testing Market 2014-2018: PerkinElmer Inc., Quest Diagnostics Inc., Sequenom Inc., and Verinata Health Dominate the Industry" report to their offering. The Prenatal Testing market in the US is experiencing a significant increase in the number of new tests being launched in the market. For instance, Sequenom launched Laboratoire Cerba's non-invasive prenatal test in San Diego, California, and Saint-Ouen-L'Aum?ne, France, in December 2013 and enhanced the sequencing series for its MaterniT21 PLUS laboratory-developed test in October 2013. Moreover, PerkinElmer Inc. expanded its prenatal screening test offerings, introducing the first early onset preeclampsia screening test in the US in August 2013. This trend will have a positive impact on the growth of the market. According to the report, one of the major factors driving the market is the increase in the incidence of fetal abnormalities such as Down syndrome, Edwards syndrome, neural tube defects, and genetic defects and disorders such as sickle cell anemia, thalassemia, spina bifida, Tay Sachs disease, cystic fibrosis, muscular dystrophy, cleft palate, and fragile X syndrome. Further, the report states that one of the major challenges is the decline in fertility rates all over the world. The decline in the fertility rate will lead to a decline in pregnancies, which in turn will lead to a reduction in the demand for prenatal testing during the forecast period. Key vendors dominating this space are: - PerkinElmer Inc - Quest Diagnostics Inc. - Sequenom Inc. - Verinata Health Inc. Other vendors mentioned in the report are: - ANGLE plc - Ariosa Diagnostics Inc - BGI Health - CellScape Corp - Fluidigm Corp. - Ikonisys Inc - Kellbenx Inc - Natera Inc - Ravgen Inc. - Trovagene Inc. For more information visit http://www.researchandmarkets.com/research/7l...al_testing
Fluidigm to Announce Q1 2014 Financial Results and Host Conference Call for Investors
Business Wire - Wed Apr 23, 7:00PM CDT
Fluidigm Corporation (NASDAQ:FLDM) will report its first quarter 2014 financial results on May 5, 2014, after close of market.
Dividends, Recognition for Innovative Technologies, Stock Price Movements, and Schedule of Conference Calls and Earnings - Analyst Notes on Allegion, Medidata, Mettler-Toledo, WebMD, and Fluidigm
PR Newswire - Tue Apr 22, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Allegion plc (NYSE: ALLE), Medidata Solutions, Inc. (NASDAQ: MDSO), Mettler-Toledo International, Inc. (NYSE: MTD), WebMD Health Corp. (NASDAQ: WBMD) Fluidigm Corporation (NASDAQ: FLDM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1199-100free
Why Fluidigm (FLDM) Stock Is Up Today
at The Street - Mon Apr 14, 11:02AM CDT
Fluidigm (FLDM) shares are up in trading on Monday following an analysts upgrade.
Fluidigm (FLDM) is now in Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 7:54AM CDT
Fluidigm (FLDM) is now in Oversold Territory
Analyst Bullish On Medical Research, Equipment Stocks
at Investor's Business Daily - Tue Apr 08, 12:33PM CDT
A new analyst report from Cowen & Co. offers an upbeat assessment of medical research and equipment stocks ahead of first-quarter earnings, thanks to improving end markets. In his report on the Life Sciences and Diagnostic Tools sectors on Tuesday,...
Insider Trading Alert - BHI, FLDM And CTAS Traded By Insiders
at The Street - Fri Apr 04, 9:30AM CDT
Stocks with insider trader activity include BHI, FLDM and CTAS
Single Cell Omics Trends - Global Market Overivew 2014
M2 - Tue Apr 01, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j5vvw9/single_cell_omics) has announced the addition of the "Single Cell Omics Trends" report to their offering. Single Cell Omics, a cutting edge technology, mainly integrates advanced technology with biology for a variety of single cell applications. The technology helps to study single cells at a much deeper level which allows identifying important genomic variations. The report analyzes and presents an overview of Single Cell Omics market worldwide. The report also offers global market estimates and projections for Single Cell Omics technology and products in US dollars for years 2012 through 2017. Key geographic market quantitatively analysed include the Unites States, Europe, Asia Pacific, and Japan. Supported with 6 market data tables, the report provides a review of market trends, application areas, growth opportunities, and challenges. The data table highlights global Single Cell Omics market by applications, technology, product, region, and field of study. Key Topics Covered: 1. SINGLE CELL OMICS - A MARKET OVERVIEW - Single Cell Analysis - A Revolutionary Technology Changing Market Dynamics - Single Cell Genomics - An Introduction - Biological Research Shifting from Tissue/Organ Level Approach to a Single Cell - Single Cell Analysis - Role of Omics - Single-Cell Isolation Techniques - Single Cell Omics - Applications - Single Cell Omics - Major Application Areas - SCA Devices - Technological Improvements - Single Cell Omics - Growth Opportunities Vs. Challenges - Global Single Cell Omics Market to Register Mammoth Growth Rate - Single Cell Omics Market by Technology - Single Cell Omics Market by Field of Study - Single Cell Omics Market by Applications - Picodroplet Single Cell Analysis Technology Witnesses Significant Surge - Major Players in the Single Cell Isolation Market - Major Players in the Single Cell Sample Preparation Market - Major Players in the Single Cell Genomic Analysis Market 2. RECENT INDUSTRY ACTIVITY - Genome Institute of Singapore and Fluidigm Open GIS-Fluidigm - Single-Cell Omics Center in Singapore - Sphere Fluidics Develops New Technologies for Single Cell Analysis 3. MARKET PARTICIPANTS - BD Biosciences - BioNano Genomics, Inc. - DVS Sciences, Inc. - Fluidigm Corporation - Fluxion Biosciences, Inc. - Life Technologies Corporation - Molecular Machines & Industries (MMI) - NanoString Technologies, Inc. - NuGEN Technologies, Inc. - Qiagen NV - Roche Applied Science - Silicon Biosystems - Sphere Fluidics Ltd. - Tataa Biocenter AB - Thermo Fisher, HCA Company 4. APPENDIX For more information visit http://www.researchandmarkets.com/research/j5...cell_omics
Global Biochips Market 2012-2016: Major Challenge for Market is High Cost Incurred in the Implementation of Biochips
M2 - Thu Mar 20, 11:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bcvpcl/global_biochips) has announced the addition of the "Global Biochips Market 2012-2016" report to their offering. The analysts forecast the Global Biochips market to grow at a CAGR of 19.1 percent over the period 2012-2016. One of the key factors contributing to this market growth is the growing need for high speed diagnosis. The Global Biochips market has also been witnessing the high cost of deployment. However, the increasing outsourcing activities could pose a challenge to the growth of this market. Key vendors dominating this space include Affymetrix Inc., Illumina, Inc., GE Healthcare Ltd. and Agilent Technologies Inc. Other vendors mentioned in the report are Bio-Rad Laboratories Inc., Biomrieux Sa, Caliper Life Sciences Inc., Cephied Inc., Fluidigm Corp., Life Technologies Corp., Cybrdi Inc., Gamida For Life Group, Origene Technologies Inc., Perkinelmer Inc., Roche Nimblegen Inc., Sigma Aldrich Corp, Isu Abxis Co. Ltd, and Us Biomax Inc. Commenting on the report, an analyst from the Hardware team said: ''Over the years, numerous drug manufacturers have been outsourcing their drug development processes to contract research organizations. Outsourcing activities reduce manufacturing and distribution costs, ensure quality of service, and reduce lead time. They also help the sourcing companies to manage product demand and to concentrate on other competencies such as innovation and brand building. These contract research organizations employ the latest technologies and sophisticated instruments, and thus increased outsourcing to such organizations is a positive trend for the Global Biochips market.'' According to the report, one of the major drivers is the growing need for high speed diagnosis from patients and doctors. Biochips are specially designed with advanced technology that makes them ultra-efficient, therefore, enhancing their operating speed to a great extent. For more information visit http://www.researchandmarkets.com/research/bc...l_biochips About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Concise Analysis of the International qPCR and dPCR Instrumentation Market
M2 - Tue Mar 18, 4:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f2m2mm/qpcr_and_dpcr) has announced the addition of the "Concise Analysis of the International qPCR and dPCR Instrumentation Market" report to their offering. This report analyzes the worldwide markets for qPCR and dPCR Instrumentation in US$ Million. The Global market is further analyzed by the following Product Segments and End-Use Markets: Product Segments - qPCR (quantitative Polymerase Chain Reaction), and dPCR (digital Polymerase Chain Reaction); End-Use markets - Educational/Research, Testing Laboratories, and Pharma. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East/Africa, and Latin America. Annual estimates and forecasts are provided for the period 2009 through 2018. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 49 companies including many key and niche players such as: - Agilent Technologies - Biofire Diagnostics, Inc. - Bio-Rad Laboratories, Inc. - Cepheid - Eppendorf AG - Exiqon A/S - F. Hoffmann-La Roche Ltd. - Fluidigm Corporation - Illumina, Inc. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. Key Topics Covered: I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW 2. MAJOR TRENDS & ISSUES 3. COMPETITION 4. END-USE MARKET ANALYSIS 5. PRODUCT OVERVIEW 6. INSIGHT INTO GLOBAL SPENDING ON LIFE SCIENCES RESEARCH 7. PRODUCT INNOVATIONS/ INTRODUCTIONS 8. RECENT INDUSTRY ACTIVITY 9. FOCUS ON SELECT GLOBAL PLAYERS 10. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. MIDDLE EAST & AFRICA 7. LATIN AMERICA IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 49 (including Divisions/Subsidiaries - 51) - The United States (29) - Canada (1) - Japan (1) - Europe (19) - Germany (7) - The United Kingdom (2) - Spain (1) - Rest of Europe (9) - Asia-Pacific (Excluding Japan) (1) For more information visit http://www.researchandmarkets.com/research/f2...r_and_dpcr
Microfluidics Market Report 2013-2018: Materials, Pharmaceuticals, Drug Delivery Devices & IVD
M2 - Fri Mar 14, 9:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7zswzc/microfluidics Normal 0 false false false EN-IE X-NONE X-NONE ) has announced the addition of the "Microfluidics Market Report 2013-2018: Materials, Pharmaceuticals, Drug Delivery Devices & IVD" report to their offering. The microfluidics market is segmented based on materials, products, and applications. This report studies market trends for the above mentioned segments in three industries, namely, pharmaceutical, in-vitro diagnostics, and drug delivery devices. The market is expected to grow at a strong CAGR during the study period. This is due to factors such as the rising demand for POC devices, quick return on investments provided by microfluidics devices which helps in cost reductions, and miniaturization of microfluidic chips. However, factors such as difficulty in incorporation of emerging microfluidic technologies into existing workflows and complex and time consuming regulatory standards are hampering the growth of this market. Microfluidics is defined as the science of designing, fabricating, and formulating products and processes that deal with low volumes of fluids in the range of nanoliters or picoliters. The technology evolved from MEMS (Micro Electro Mechanical Systems) devices and can replicate all the functions of its counterparts in various healthcare applications such as, drug delivery, Point-of-Care (POC), and clinical diagnostics. This study covers the materials, industries, and applications revenue markets for the global market. The global revenue generated from various microfluidics products used in three industries, namely, pharmaceutical, in-vitro diagnostics, and drug delivery devices is considered to estimate the market size. Material - Polymer-based Microfluidics - Glass-based Microfluidics - Silicon-based Microfluidics - Other Material-based Microfluidics Industry Pharmaceuticals - -- Microfluidic Chips for Laboratory Analytics - --- Toxicity Screening - --- Proteomics Analysis - --- Gene Sequencing - --- Capillary Electrophoresis - -- Accurate Dispensing Devices - -- Microreactors for Drug Synthesis - -- In-Vitro Diagnostics - --- Clinical Diagnostics - --- Point--- of--- Care Testing - --- Environmental Testing - --- Industrial Testing - --- Agro Food Testing - -- Drug Delivery Devices - --- Inhaler Nozzles - --- Micro Needles - --- Micro Pumps Application - Drug Delivery - Industrial and Environmental - Analytical Devices - Pharmaceutical and Life Sciences Research - Point-of-Care Diagnostics - Clinical and Veterinary Diagnostics Companies Mentioned - Abbott Laboratories, Inc. - Agilent Technologies - Bartels Mikrotechnik Gmbh - Becton, Dickinson And Company 1 Becton Drive - Bio-Rad Laboratories, Inc. - Biofluidix Gmbh - Cepheid, Inc. - Danaher Corporation - Fluidigm Corporation - Johnson & Johnson - Life Technologies Corporation - Microfluidic Chipshop Gmbh - Perkinelmer, Inc. - Raindance Technologies - Roche Diagnostics Limited - Scienion Ag - Siemens Healthcare For more information visit http://www.researchandmarkets.com/research/7z...rofluidics Normal 0 false false false EN-IE X-NONE X-NONE
Fluidigm to Present at the Cowen and Company 34th Annual Health Care Conference
Business Wire - Wed Feb 26, 8:01AM CST
Fluidigm Corporation (NASDAQ:FLDM) today announced that it will present at the Cowen and Company 34th Annual Health Care Conference in Boston, on Tuesday, March 4, 2014, at 8:40 a.m. (EST).
Prenatal Testing Market in the US 2014-2018: Perkinelmer Inc. Expands its Screening Test Offerings, Introducing the First Early Onset Preeclampsia Screening Test in the US in 2013
M2 - Tue Feb 25, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/x2lvh8/prenatal_testing) has announced the addition of the "Prenatal Testing Market in the US 2014-2018" report to their offering. The analysts forecast the Prenatal Testing market in the US to grow at a CAGR of 5.43 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing incidence of fetal health-related abnormalities. The Prenatal Testing market in the US has also been witnessing the significant increase in the launch of new tests. However, the falling fertility rates in the US could pose a challenge to the growth of this market. Key vendors dominating this space are PerkinElmer Inc., Quest Diagnostics Inc., Sequenom Inc., and Verinata Health Inc. Other vendors mentioned in the report are ANGLE plc, Ariosa Diagnostics Inc., BGI Health, CellScape Corp., Fluidigm Corp., Ikonisys Inc., Kellbenx Inc., Natera Inc., Ravgen Inc., and Trovagene Inc. Commenting on the report, an analyst from the team said: The Prenatal Testing market in the US is experiencing a significant increase in the number of new tests being launched in the market. For instance, Sequenom launched Laboratoire Cerba's non-invasive prenatal test in San Diego, California, and Saint-Ouen-L'Aumone, France, in December 2013 and enhanced the sequencing series for its MaterniT21 PLUS laboratory-developed test in October 2013. Moreover, PerkinElmer Inc. expanded its prenatal screening test offerings, introducing the first early onset preeclampsia screening test in the US in August 2013. This trend will have a positive impact on the growth of the market. According to the report, one of the major factors driving the market is the increase in the incidence of fetal abnormalities such as Down syndrome, Edwards syndrome, neural tube defects, and genetic defects and disorders such as sickle cell anemia, thalassemia, spina bifida, Tay Sachs disease, cystic fibrosis, muscular dystrophy, cleft palate and fragile X syndrome. For more information visit http://www.researchandmarkets.com/research/x2...al_testing About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.